Single-fraction stereotactic radiosurgery for residual, recurrent, or metastatic intracranial solitary fibrous tumors: An IRRF study toward management guidance
Neuro-Oncology · 2026
DOI: 10.1093/neuonc/noag007 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Neuro-Oncology, 2026. Verfasst von Salem M Tos und 40 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurological Surgery, University of Virginia, Charlottesville, Virginia, USA. Hauptthemen laut MEDLINE: Radiosurgery, Neoplasm Recurrence, Local, Solitary Fibrous Tumors, Brain Neoplasms. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Intracranial solitary fibrous tumors (SFTs) are rare, aggressive neoplasms with high local recurrence. This study evaluates the efficacy and prognostic factors of single-fraction stereotactic radiosurgery (SRS).
Methods
This multicenter retrospective study included 107 patients (253 SFTs) treated with single-fraction SRS at 18 centers (1989-2024). We analyzed local control (LC), intracranial tumor control (ITC), overall tumor control (OTC), progression-free survival (PFS), disease-specific survival (DSS), and overall survival (OS). Cox regression identified prognostic factors.
Results
Median follow-up was 33 months. LC was 68.4% (5-year: 56.8% and 10-year: 38.8%). ITC 54.2% (5-year: 48.5%) and OTC 50.5% (5-year: 44.0%). PFS was 56.3% and 30.2% at 5 and 10 years, respectively. DSS remained high at 89.7% (5-year) and 79.7% (10-year), while OS was 79.3% (5-year) and 55.2% (10-year). Independent predictors of LC included recurrent versus metastatic SFTs (HR: 1.96, P = 0.028), margin dose ≤16 Gy (HR: 2.35, P = 0.006), larger tumor volume (HR: 1.05, P < 0.001), and longer diagnosis-to-SRS duration (HR: 1.02, P < 0.001). Older age (HR: 1.03, P = 0.014) and longer resection-to-SRS duration (HR: 1.02, P = 0.018) predicted worse ITC. Age significantly affected OS (HR: 1.06, P < 0.001) and PFS (HR: 1.03, P = 0.037). Longer diagnosis-to-SRS (HR: 1.03, P = 0.002) and resection-to-SRS durations (HR: 1.02, P = 0.030) predicted worse PFS. KPS score >70 predicted better outcomes across ITC, OTC, DSS, and OS. Radiation-related adverse effects occurred in 2.8%.
Conclusion
Single-fraction stereotactic radiosurgery offers reasonable tumor control and favorable long-term survival in the adjuvant and salvage setting for patients with residual, recurrent, or metastatic intracranial SFTs. Key prognostic factors included tumor volume, recurrence status, and timing of SRS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurological Surgery, University of Virginia, Charlottesville, Virginia, USA.
- Department of Neurological Surgery, University of Pittsburgh Medical Center (UPMC), Pennsylvania, USA.
- Department of Neurosurgery, Koc University Hospital, Istanbul, Turkey.
- Vivian L. Smith Department of Neurosurgery, University of Texas Health Science Center, Houston, Texas, USA (C.A.-C., A.B.-G., A.I.B., Y.E.).
- Department of Neurosurgery, GMC, Chandigarh, India.
- Department of Neurosurgery, Université de Sherbrooke, Centre de recherche du CHUS, Quebec, Canada.
ORCID-Profile: Salem M Tos, Yuki Shinya, Yoshua Esquenazi
Zitieren
APA
Tos, S. M., Shaaban, A., Hamdan, D., Mantziaris, G., Hajikarimloo, B., Ishaque, M., Shinya, Y., Lohia, V., Wei, Z., Askeroglu, O., Amezquita-Contreras, C., Becerril-Gaitan, A., Verma, O., Douri, K., Lora, N., de Moura, A. C. M. A., Yap, E., Bailey, D., Speckter, H., …, & Sheehan, J. P. (2026). Single-fraction stereotactic radiosurgery for residual, recurrent, or metastatic intracranial solitary fibrous tumors: An IRRF study toward management guidance. Neuro-Oncology. https://doi.org/10.1093/neuonc/noag007
Vancouver
Tos SM, Shaaban A, Hamdan D, Mantziaris G, Hajikarimloo B, Ishaque M, et al. Single-fraction stereotactic radiosurgery for residual, recurrent, or metastatic intracranial solitary fibrous tumors: An IRRF study toward management guidance. Neuro-Oncology. 2026. doi:10.1093/neuonc/noag007
BibTeX
@article{Tos2026,
author = {Tos, Salem M and Shaaban, Ahmed and Hamdan, Dawoud and Mantziaris, Georgios and Hajikarimloo, Bardia and Ishaque, Mariam and Shinya, Yuki and Lohia, Vanshika and Wei, Zhishuo and Askeroglu, Orbay and Amezquita-Contreras, Christian and Becerril-Gaitan, Andrea and Verma, Onam and Douri, Keiss and Lora, Nathalia and de Moura, Anais C M A and Yap, Eugene and Bailey, David and Speckter, Herwin and Cohen, Salomon Cohen and Benjamin, Carolina and Blanco, Angel I and Esquenazi, Yoshua and Tripathi, Manjul and Zacharia, Brad E and Warnick, Ronald E and Liscak, Roman and Guseynova, Khumar and Lee, Cheng-Chia and Yang, Huai-Che and Franzini, Andrea and Picozzi, Piero and Duzkalir, Haluk and Peker, Selcuk and Palmer, Joshua D and Mathieu, David and Bowden, Greg N and Niranjan, Ajay and Lunsford, L Dade and Kondziolka, Douglas and Sheehan, Jason P},
title = {Single-fraction stereotactic radiosurgery for residual, recurrent, or metastatic intracranial solitary fibrous tumors: An IRRF study toward management guidance},
journal = {Neuro-Oncology},
year = {2026},
doi = {10.1093/neuonc/noag007}
}
EUVIMED